MEASURING THE IMPACT OF ONCHOCERCIASIS CONTROL AND ELIMINATION PROBRA

描述（由申请人提供）：拟议的项目有两个目标，将在盘尾丝虫病流行的三个非洲国家（乌干达、刚果民主共和国和埃塞俄比亚）实施。目标1的拟议项目将设法衡量 盘尾丝虫病控制和消除方案。更具体地说，我们寻求评估 随着大规模给药（MDA）的进展，盘尾丝虫感染生物标志物的演变， 并评估在以下地区盘尾丝虫感染诊断工具的性能： 接近传输中断。将通过便利抽样招募受访者参与研究。按照招标书中的指示，我们力求为目标1招募1，500名参与者，为目标2招募3，000名参与者。受试者将接受体格、口腔和血清学检查。从收集的数据中产生的信息将有助于决策者了解情况，从而有效地促进和加强消除NTD的努力。目标2的项目旨在测量使用大规模药物管理（MDA）的盘尾丝虫病控制和消除计划对共同流行的淋巴丝虫病（LF）的影响。更具体地说，该项目力求制定一项标准化方案，以评价盘尾丝虫病和淋巴丝虫病重叠地区的淋巴丝虫病状况;评价大规模施用伊维菌素控制盘尾丝虫病对减少淋巴丝虫病流行和传播的影响;在LF执行单位中，（区），比较接受伊维菌素MDA和未接受伊维菌素MDA的社区之间LF的患病率。将在选定的实施单位中通过方便抽样。将对被调查者进行体格、口腔、血清学和显微镜检查。从收集的数据中产生的信息将有助于向决策者提供信息，以便有效地促进和加强消除NTD的努力，并有可能呼吁将盘尾丝虫病和LF结合起来。

DESCRIPTION (provided by applicant): The proposed project has two objectives which will be implemented in three African countries (Uganda, DRC, and Ethiopia) which are endemic for onchocerciasis. The proposed project for Objective 1 will seek to measure the impact of onchocerciasis control and elimination programs. More specifically we seek to evaluate the evolution of biomarkers of onchocercial infection as mass drug administration (MDA) progresses, and to evaluate the performance of diagnostic tools for onchocercial infection in areas that are approaching the interruption of transmission. Recruitment of respondents into the study will be via convenience sampling. For Objective 1 we seek to recruit 1,500 participants, and for the second objective, 3000 participants, in conformance with the instructions in the request for proposals. Participants will be subjected to physical, oral and serologic examinations. Information generated from collected data will serve to inform policy makers so as to effectively promote and strengthen NTD elimination efforts. The project for Objective 2 seeks to measure the impact of onchocerciasis control and elimination programs using mass drug administration (MDA) on coendemic lymphatic filariasis (LF). More specifically the project seeks to develop a standardized protocol to evaluate the status of LF in the areas of onchocerciasis and LF overlap; evaluate the impact of mass drug administration of ivermectin for the control of onchocerciasis on reducing the prevalence and transmission of lymphatic filariasis (LF); and in LF implementation units (district), compare prevalence of LF between communities that have received ivermectin MDA with those that have not received it. Recruitment of respondents into the study will be via convenience sampling in the selected implementation units. Physical, oral and serologic and microscopic examinations will be performed on respondents. Information generated from collected data will serve to inform policy makers so as to effectively promote and strengthen NTD elimination efforts, with a possibility of calling for integration of onchocerciasis and LF.